An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and aPTT

Schött, Ulf; Rundgren, Malin; Engström, M

Published in:
Journal of Thrombosis and Haemostasis

DOI:
10.1111/j.1538-7836.2009.03473_2.x

2009

Citation for published version (APA):
AN EVALUATION OF MONITORING POSSIBILITIES OF ARGATROBAN USING ROTATIONAL THROMBOELASTOMETRY AND APTT

U. Schott*1,2, M. Rundgren1, M. Engström2
1Anesthesia and Intensive Care, University Hospital in Lund, Lund Sweden, 2Anesthesia and Intensive Care, Halmstad Central Hospital, Halmstad, Sweden

Conclusion
A significant and strong correlation between argatroban concentrations and several ROTATIONAL THROMBOELASTOMETRY (ROTEM®) parameters were found, especially so in the clinically relevant therapeutic range up to 100 s aPTT for patients with heparin induced thrombocytopenia (HIT). Rotational thrombelastometry/thrombelastography has a potential role to increase the safety of argatroban anticoagulation in critically ill patients, like patients with heparin induced thrombocytopenia (HIT).

Introduction: The aim of the study was to study in vitro argatroban anticoagulation with ROTEM® and activated partial thromboplastin time (aPTT).

Method: Argatroban was added in vitro to a series of citrated whole blood samples from 10 healthy volunteers to obtain whole blood concentrations of 0, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 mg/l. Whole blood aPTT was analysed with a Free Oscillation Rheometer (FOR or ReoRox®, Medirox Sweden) and thromboelastometry ROTEM® (Pentapharm GmbH, Munich Germany).

Results: There was a significant and strong correlation between argatroban concentrations and Clotting Time (CT in ROTEM® analysis with INTEM) (p<0.0001 and r=0.98). When we studied the correlation between aPTT and CT, we found a highly significant and strong correlation between these two analyses (p<0.0001 and r=0.97). See figs 1-3.

References: